A 28-year-old woman with a history of intravenous drug use presents with a 5-day history of right shoulder pain, fever (39.2°C), and progressive loss of shoulder mobility. She admits to injecting heroin into her right antecubital fossa 2 weeks ago. On examination, the right shoulder is warm, swollen, and exquisitely tender with severe pain on passive abduction and external rotation. Synovial fluid obtained by arthrocentesis shows WBC 120,000/μL (92% neutrophils), glucose 8 mg/dL (serum glucose 95 mg/dL), protein 7.1 g/dL, and Gram stain shows Gram-positive cocci in clusters. Blood cultures grow the same organism. What is the most appropriate initial antibiotic regimen?

Explanation

## Diagnosis & Organism Identification This patient has **acute septic arthritis caused by Staphylococcus aureus**, confirmed by: - Gram-positive cocci in clusters (pathognomonic for Staph aureus) - Positive blood cultures with the same organism (bacteremia) - Severe synovial inflammation (WBC >100,000/μL, very low glucose) - Risk factor: intravenous drug use (IVDU) ### High-Yield: IVDU & Septic Arthritis **High-Yield:** Intravenous drug users have a dramatically elevated risk of **Staphylococcus aureus septic arthritis**, particularly involving the **shoulder, sternoclavicular joint, and hip**. This is due to: 1. Direct inoculation of skin flora (S. aureus) during injection 2. Immunosuppression from repeated infections and poor hygiene 3. Hematogenous seeding from bacteremia ### Antibiotic Selection: The Critical Issue The key decision is whether to assume **methicillin-susceptible S. aureus (MSSA)** or **methicillin-resistant S. aureus (MRSA)**. **Clinical Pearl:** In the setting of **community-acquired septic arthritis from IVDU**, the prevalence of MRSA is now **40–60% in many regions**. Therefore, **empiric coverage for both MSSA and MRSA is mandatory** until susceptibilities are known. ### Recommended Empiric Regimen | Regimen | Rationale | Coverage | |---------|-----------|----------| | **Vancomycin + Nafcillin** | Vancomycin covers MRSA; nafcillin covers MSSA with superior penetration and bactericidal activity | Both MSSA & MRSA | | Ceftriaxone monotherapy | 3rd-generation cephalosporin; limited MRSA coverage; not adequate empirically | MSSA only | | Clindamycin monotherapy | Good bone/joint penetration but resistance rates increasing; not empiric standard | Partial coverage | | Penicillin G monotherapy | No MRSA coverage; inadequate for empiric therapy | MSSA only | ### Mnemonic: EMPIRIC Coverage for Staph in IVDU **MRSA-FIRST = Must Rule out MRSA in IVDU Septic Arthritis** - **M**ethicillin-resistant is common in IVDU - **R**equires vancomycin for empiric coverage - **S**ynergistic therapy (vancomycin + nafcillin) is gold standard - **A**void monotherapy until susceptibilities known - **F**irst-line: Vancomycin + antistaphylococcal beta-lactam - **I**VDU patients: High MRSA prevalence - **R**esistance patterns: Assume MRSA until proven otherwise - **S**usceptibilities: Guide de-escalation after culture results - **T**herapy duration: 4–6 weeks IV antibiotics ### Why Vancomycin + Nafcillin? 1. **Vancomycin**: Covers MRSA; achieves excellent synovial fluid penetration (especially with inflamed joint) 2. **Nafcillin**: Superior to vancomycin for MSSA (lower MICs, better bactericidal activity, better cartilage penetration) 3. **Synergy**: Combined therapy provides broader coverage and optimal outcomes 4. **De-escalation**: Once susceptibilities are known, can switch to nafcillin monotherapy if MSSA is confirmed ### Key Point **Key Point:** Empiric therapy for suspected Staph aureus septic arthritis in IVDU must cover **both MSSA and MRSA** until culture susceptibilities are available. Vancomycin + nafcillin is the gold standard. Monotherapy with cephalosporins, clindamycin, or penicillin is inadequate.